Transarterial radioembolization (TARE) with yttrium-90 glass microspheres is widely used to treat primary and secondary malignancies in the liver. However, the safety and efficacy of TARE in patients with liver-dominant metastatic castration-resistant prostate cancer (mCRPC) is unknown. A proof-of-concept, retrospective analysis of 7 consecutive patients with liver-dominant mCRPC who were treated with TARE was performed. The median overall survival was 27.2, 32.1, and 108.1 months from the time of TARE, the diagnosis of liver metastases, and initial cancer diagnosis, respectively. The median liver progression-free survival was 7.3 months. No grade 3 or higher adverse effects were noted. TARE was found to be a safe and effective tool for treating patients with liver-dominant mCRPC in this limited cohort.

钇90玻璃微球经动脉放射栓塞术（TARE）广泛用于治疗肝脏的原发性和继发性恶性肿瘤。然而，TARE 在肝脏为主的转移性去势抵抗性前列腺癌 (mCRPC) 患者中的安全性和有效性尚不清楚。对连续 7 例接受 TARE 治疗的肝脏为主的 mCRPC 患者进行了概念验证、回顾性分析。从 TARE、肝转移诊断和初始癌症诊断开始，中位总生存期分别为 27.2、32.1 和 108.1 个月。中位肝脏无进展生存期为 7.3 个月。未发现 3 级或更高级别的不良反应。在这个有限的队列中，TARE 被发现是治疗以肝脏为主的 mCRPC 患者的一种安全有效的工具。